UY35548A - Péptidos terapéuticos para el tratamiento de trastornos metabólicos. - Google Patents

Péptidos terapéuticos para el tratamiento de trastornos metabólicos.

Info

Publication number
UY35548A
UY35548A UY0001035548A UY35548A UY35548A UY 35548 A UY35548 A UY 35548A UY 0001035548 A UY0001035548 A UY 0001035548A UY 35548 A UY35548 A UY 35548A UY 35548 A UY35548 A UY 35548A
Authority
UY
Uruguay
Prior art keywords
treatment
metabolic disorders
therapeutic peptides
pyy
novel
Prior art date
Application number
UY0001035548A
Other languages
English (en)
Inventor
Steven Thomas Dock
Andrew James Carpenter
Robert Neil Hunter Iii
Ved P Srivastava
Wu Yulin
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of UY35548A publication Critical patent/UY35548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)

Abstract

La presente invención se refiere a análogos novedosos de PYY que tienen un perfil terapéutico mejorado cuando se comparan con el PYY humano nativo. Estos análogos novedosos de PYY son útiles en el tr atamiento de obesidad, diabetes, y otros trastornos.
UY0001035548A 2013-05-02 2014-04-30 Péptidos terapéuticos para el tratamiento de trastornos metabólicos. UY35548A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361818624P 2013-05-02 2013-05-02

Publications (1)

Publication Number Publication Date
UY35548A true UY35548A (es) 2014-11-28

Family

ID=50842285

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035548A UY35548A (es) 2013-05-02 2014-04-30 Péptidos terapéuticos para el tratamiento de trastornos metabólicos.

Country Status (20)

Country Link
US (2) US20160108098A1 (es)
EP (1) EP2992008B1 (es)
JP (1) JP2016519130A (es)
KR (1) KR20160003848A (es)
CN (1) CN105263957A (es)
AR (1) AR096162A1 (es)
AU (1) AU2014261111B2 (es)
BR (1) BR112015027528B1 (es)
CA (1) CA2909045C (es)
CL (1) CL2015003199A1 (es)
EA (1) EA201591839A1 (es)
ES (1) ES2732291T3 (es)
HK (1) HK1214829A1 (es)
MX (1) MX2015015249A (es)
PE (1) PE20151808A1 (es)
RU (1) RU2015144632A (es)
SG (1) SG11201508469YA (es)
TW (1) TW201534616A (es)
UY (1) UY35548A (es)
WO (1) WO2014178018A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
BR112015027528B1 (pt) * 2013-05-02 2023-02-14 Glaxosmithkline Intellectual Property Development Limited Polipeptídeo, forma de sal, combinação farmacêutica e composição farmacêutica
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US9085637B2 (en) * 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2016124687A1 (en) * 2015-02-04 2016-08-11 Novo Nordisk A/S Selective pyy compounds and uses thereof
JP6731958B2 (ja) 2015-06-12 2020-07-29 ノヴォ ノルディスク アー／エス 選択的ｐｙｙ化合物及びその使用
CN108473979B (zh) * 2015-12-28 2022-08-19 出光兴产株式会社 肽标签及包含它的带有标签的蛋白质
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
KR20190126335A (ko) 2017-03-08 2019-11-11 인타르시아 세라퓨틱스 인코포레이티드 약물 전달 장치로부터 메스꺼움 유발 화합물을 투여하기 위한 장치 및 방법
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202208410A (zh) * 2018-11-01 2022-03-01 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CA3156452A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh NPY2 RECEPTOR AGONISTS
IL293460A (en) * 2019-12-04 2022-07-01 Scripps Research Inst 2glp receptor agonists and methods of using them
MX2022013024A (es) * 2020-04-17 2023-03-15 I2O Therapeutics Inc Analogos del peptido tirosina tirosina (pyy) de accion prolongada y metodos de uso de los mismos.
EP4192853A1 (en) 2020-08-07 2023-06-14 Boehringer Ingelheim International GmbH Soluble npy2 receptor agonists
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN117603364A (zh) * 2022-09-30 2024-02-27 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
PT966297E (pt) 1996-08-08 2009-03-18 Amylin Pharmaceuticals Inc Regulação da motilidade gastrintestinal
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
JP2001523688A (ja) 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規エキセンジン・アゴニスト化合物
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
KR100902625B1 (ko) 2000-08-15 2009-06-15 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 마이크로입자
AU2002332054B2 (en) * 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
EP1789440A4 (en) * 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
CN101027075A (zh) * 2004-09-24 2007-08-29 默克公司 用于治疗肥胖的组合疗法
CA2588594C (en) * 2004-12-13 2014-02-18 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
CA2646704A1 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
CN102666586A (zh) 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
WO2011050008A2 (en) * 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
EP2600887A4 (en) * 2010-07-09 2014-01-22 Amylin Pharmaceuticals Llc MICROCRYSTALLINE AGONISTS OF Y-RECEPTORS
GB201101459D0 (en) * 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
BR112015027528B1 (pt) * 2013-05-02 2023-02-14 Glaxosmithkline Intellectual Property Development Limited Polipeptídeo, forma de sal, combinação farmacêutica e composição farmacêutica
US9085637B2 (en) * 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof

Also Published As

Publication number Publication date
EA201591839A1 (ru) 2016-05-31
RU2015144632A (ru) 2017-06-07
ES2732291T3 (es) 2019-11-21
CA2909045A1 (en) 2014-11-06
CL2015003199A1 (es) 2016-05-06
WO2014178018A1 (en) 2014-11-06
US20140329742A1 (en) 2014-11-06
SG11201508469YA (en) 2015-11-27
US9441023B2 (en) 2016-09-13
BR112015027528A2 (pt) 2017-12-05
BR112015027528B1 (pt) 2023-02-14
JP2016519130A (ja) 2016-06-30
AR096162A1 (es) 2015-12-09
PE20151808A1 (es) 2015-12-16
KR20160003848A (ko) 2016-01-11
CA2909045C (en) 2022-12-06
US20160108098A1 (en) 2016-04-21
EP2992008B1 (en) 2019-04-10
TW201534616A (zh) 2015-09-16
AU2014261111A1 (en) 2015-11-19
EP2992008A1 (en) 2016-03-09
HK1214829A1 (zh) 2016-08-05
AU2014261111B2 (en) 2017-03-16
CN105263957A (zh) 2016-01-20
MX2015015249A (es) 2016-02-09

Similar Documents

Publication Publication Date Title
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
SV2017005594A (es) Compuestos co-agonistas de glucagon y glp-1
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
MX2016004907A (es) Analogos del glucagon.
CO7400885A2 (es) Análogos de glucagón
BR112016022465A2 (pt) agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4
CO2018000809A2 (es) Anticuerpos para cd40
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
UY34859A (es) Análogos peptídicos de la exendina 4.
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CL2016000190A1 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.
BR112018067731A2 (pt) coagonistas de glucagon e glp-1 para o tratamento de obesidade
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
ECSP16075416A (es) Anticuerpos de il-21
BR112018010155A2 (pt) segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
CL2016001786A1 (es) Regulación del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206